On June 12, 2019, the Minister of Health tabled the final report, A Prescription for Canada: Achieving Pharmacare for All, from the Advisory Council on the Implementation of National Pharmacare (the Council) (see also: news release and backgrounder). The Council recommends that Canada implement universal, single-payer, public pharmacare by enacting new legislation, and proceeding in a stepwise approach to implementation. As reported previously, the 2019 Federal Budget announced funding for some of the steps, including the formation of an arms-length national drug agency.
The final report outlines a timeline for implementation. By January 1, 2022, the new agency would be responsible for the creation of a national formulary, listing essential medicines covering about half of all prescriptions and most major conditions. By 2027, this initial formulary would be expanded to a fully comprehensive formulary. Also by January 1, 2022, the report calls for the establishment of a strategy for expensive drugs for rare diseases.
The Council recommends the enactment of new legislation, separate and distinct from the Canada Health Act. The legislation would outline how governments will work together and share costs, list federal responsibilities and include steps for opting in by provincial and territorial governments.
In a statement, the Minister of Health stated that the government “will carefully review the Council’s final report and its recommendations” over the coming months. However, Parliament has adjourned until September 16, 2019, and implementation of the Council’s recommendations may depend on what happens in the federal election, which is scheduled for October 21, 2019.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Health Canada aims to reduce red tape by increasing international collaboration, alignment and reliance
In July 2025, the Government of Canada launched a “Red Tape Review” across all federal departments to modernize regulatory frameworks and support economic growth.Read More -
Medical devices updates: new Health Canada guidance for determining medical device application type and Medical Devices Directorate performance reports released
In August 2025, Health Canada released the Guidance for determining medical device application type.Read More -
PM(NOC) Regulations: eighth-year anniversary of major amendments
September 21, 2025, marked the eighth anniversary of the significant amendments to the Patented Medicines (Notice of Compliance) Regulations.Read More